This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Pharma Mar Past Earnings Performance
Past criteria checks 2/6
Pharma Mar has been growing earnings at an average annual rate of 38.9%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 10.5% per year. Pharma Mar's return on equity is 13.3%, and it has net margins of 16.3%.
Key information
38.91%
Earnings growth rate
38.59%
EPS growth rate
Biotechs Industry Growth
12.91%
Revenue growth rate
10.48%
Return on equity
13.27%
Net Margin
16.25%
Last Earnings Update
31 Mar 2023
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pharma Mar makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
BMV:PHM1 N Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 23
177
29
42
85
31 Dec 22
196
49
43
83
30 Sep 22
231
84
42
83
30 Jun 22
233
85
42
84
31 Mar 22
232
91
41
76
31 Dec 21
230
93
40
72
30 Sep 21
188
63
34
61
30 Jun 21
200
67
35
58
31 Mar 21
222
91
35
56
31 Dec 20
270
137
36
54
30 Sep 20
246
147
37
48
30 Jun 20
214
124
38
47
31 Mar 20
166
72
39
48
31 Dec 19
86
-9
38
51
30 Sep 19
136
-27
58
58
30 Jun 19
84
-37
38
61
31 Mar 19
154
-24
59
69
31 Dec 18
109
-17
39
74
30 Sep 18
189
-16
66
80
30 Jun 18
128
-20
44
119
31 Mar 18
179
-26
65
79
31 Dec 17
159
-28
58
79
30 Sep 17
182
-22
67
77
30 Jun 17
186
-18
74
78
31 Mar 17
184
-19
67
78
31 Dec 16
181
-24
68
78
30 Sep 16
187
-18
68
75
30 Jun 16
188
-10
71
60
31 Mar 16
190
-7
70
66
31 Dec 15
194
7
69
60
31 Dec 14
175
13
60
46
31 Dec 13
74
12
59
0
31 Dec 12
66
10
60
0
Quality Earnings: PHM1 N has high quality earnings.
Growing Profit Margin: PHM1 N's current net profit margins (16.3%) are lower than last year (39.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHM1 N has become profitable over the past 5 years, growing earnings by 38.9% per year.
Accelerating Growth: PHM1 N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHM1 N had negative earnings growth (-68.2%) over the past year, making it difficult to compare to the Biotechs industry average (-9.8%).
Return on Equity
High ROE: PHM1 N's Return on Equity (13.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/06/12 01:11
End of Day Share Price
2023/03/16 00:00
Earnings
2023/03/31
Annual Earnings
2022/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharma Mar, S.A. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.